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Abstract Objectives Langerhans' Cell histiocytosis (LCH) is a rare disease, which remains poorly understood
and whose cellular origin remains unknown. To increase understanding of temporal bone LCH, it is necessary to
study recent advances in the diagnosis and treatment of this disease. Methods The long term(5 to 30 years) results of
21 temporal bone LCH cases treated between 1973 and 2003 were reviewed. Surgery, radiotherapy, pharmacologic
therapy or a combination of these treatments were employed in these cases. Results Eighteen patients were cured(18/
21, 85%). Six patients developed residual diabetes insipidus (DI) and dwarfism (28%). Three patients died(14%).
Conclusions The Alessi classification system for LCH based on the extent of disease accurately predicts prognosis
and is a useful guide in selecting treatment methodologies. X-ray, computed tomography and magnetic resonance im⁃
aging have proved useful in defining the extent of osseous and soft tissue diseases. Diagnosis of LCH is based on clini⁃
cal presentations, radiographic findings and histopathological results. Surgery and radiotherapy are the main treat⁃
ment modalities. Pharmacologic therapy should be used in patients with aggressive, disseminate, and refractory le⁃
sions. LCH has a predilection for children and prognosis depends on age and extent of vital organ involvement.
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Introduction
The term histiocytosis X(HX) was introduced by
Lichtenstein in 1953 to group together three conditions,
i.e., eosinophilic granuloma(EG),
Hand-Schuller-Christian syndrome(HSC) and
Letterer-Siwe disease (LS), with X meaning unknown
etiology[1]. This terminology has been used since then. In
1987, the Writing Group of the Histiocyte Society
proposed that HX be reclassified as Langerhans' cell
histiocytosis(LCH) and that the aforementioned eponyms
be replaced with specific and inclusive diagnostic terms.
The revised classification is based on contemporary
pathologic studies that clearly identify the Langerhans'
cell as the distinctive histiocyte[2]. The revised
terminology has been used by some authors but yet to be
universally accepted[3-5].
LCH is a rare and often misdiagnosed disease. The
systemic manifestations of the disease are often so
dramatic that the ear findings are overlooked. Further,
otologic findings in LCH can be confused with those of
infectious ear diseases. Otologists play an important role
in the diagnosis and management of temporal bone
LCH. It is therefore necessary to study the impact of
recent therapeutic and diagnostic advances on this
disease to increase the level of understanding of
temporal bone LCH ［6］. We reviewed the long term
results in 21 patients with temporal bone LCH who had
been treated with surgery, radiation, pharmacologic
therapy or a combination of the three from 1973 though
2003.
Original Article
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Materials and Methods
General Materials: One patient with LS was an 11
month-old boy. Three boys and 3 girls (aged between 1
and 3 years) were diagnosed with HSC. EG was
diagnosed in 14 patients(2 to 48 years of age with equal
gender distribution). The disease course ranged from 2
months to 3 years.
Symptoms and signs: Otologic presentations varied
among the patients and included ear and temporal swell⁃
ing (n = 21), skull lesions (n = 21), otorrhea (n = 17), ex⁃
ternal ear canal granuloma(n = 16), conductive hearing
loss(n = 8), sensory hearing loss(n=5) and mixed hearing
loss(n = 3). Others findings included: facial paralysis(n =
1), skin lesions(n=5), lymphoadenopathy (n = 9), hepato⁃
splenomegaly (n = 4), diabetes insipidus (DI) (n = 8),
and exophthalmos (n = 1). The LS case presented with
fever, hepatosplenomegaly, lymphoadenopathy, skin
rash (Figure 1), anemia and stomatitis. Extraskeletal
manifestations in HSC cases included low fever, hepato⁃
splenomegaly and mild anemia.
Radiographic features: Temporal bone radiographs
in EG cases demonstrated solitary, penetrative osteolytic
lesions. CT findings in these cases showed solid mass
and osteolytic bony erosions, easy to be mistaken for
malignant lesions(Figure 1). The skull radiograph in
HSC cases were characterized by multiple moth-eaten
osteolytic lesions, giving an appearance known as
"geographic skull" (Figure 2).
Laboratory: Moderate anemia was present in all 21
patients. Bone marrow aspiration showed myeloprolifera⁃
tion in 10 patients. Decreased immune function was re⁃
vealed in 6 patients. Immunoperoxidase stain was posi⁃
tive for S-100 in 5 patients.
Surgical findings: The external ear canal, middle
ear, mastoid and lesioned temporal bone were filled with
pink, grey yellow or brown-colored granular tissue,
which was often lobulated with no capsule, soft and
non-bleeding.
Histopathology: Light microscopy showed prolifera⁃
tion and infiltration of histiocytes in the LS case, and his⁃
tiocyte proliferation, eosinophil infiltration, increased fi⁃
brous tissue, hemorrage and focal necrosis in HSC speci⁃
mens. Cytoplasm of histiocyte contained small vesicles
of lipids, known as foam cells, a distinct feature of
HSC(Figure 3). EG lesions were characterized by abun⁃
dant eosinophil infiltration with multifocal aggregation,
and presence of polymorphonuclear giant cells and a
small number of plasmacytes.
Electron microscopy revealed large amount of typical
histiocytes (Langerhans' cell) with characteristic rod-or
tennis racket-shaped Birbeck granules(also referred to
as Langerhans' granules). Langerhans' cells contained
abundant cytoplasm and a lobulated nuclei with
distinctive longitudinal nuclear grooves that
differentiate them from other histiocytes. The nucleus in
Langerhans' cells was irregular or kidney-shaped in
appearance and contained euchromatin and clearly
visible nucleoli with sinking nuclear membrane
(Figure 3).
Treatments: Treatments consisted of surgery (biop⁃
sy, curettage or total excision), radiation therapy, phar⁃
macologic therapy, or a combination of these treatment
modalities. Choice of treatment was made based upon
Figure 1. An 1-year-old boy with LS. a and b. CT scans
showing a mass in the squamous part of the left temporal
bone forming penetrating osteolytic lesion that extends into
the orbit（asterisks）. c. Chest roentgenogram showing an os⁃
teolytic lesion in the right clavicle（asterisk）. d, Rashes on
the back.
Figure 2. Lateral skull radiograph of a patient with HSC
showing multiple osteolytic lesion with a moth-eaten appear⁃
ance, also known as "geographic skull".
··37
Journal of Otology 2007 Vol. 2 No. 1
the extent of disease. The purpose of surgery was to re⁃
move granular tissue for the purpose of reducing local
pressure and improving drainage. The surgery was fol⁃
lowed by low-dose radiation therapy at 600-1000cGY.
Antibiotics, corticosteroids and antidiuretics were given
as indicated by the patient's condition. Follow-ups at 5
to 30 years showed disease cure in 18 cases (85%). DI
and dwarfism were seen in 6 cases(28% ). There were
three deaths (14%), 1 LS case from secondary pneumo⁃
nia and 2 EG cases from otogenic cerebral abscess and
reportedly "cerebrovascular accident". In a case of tem⁃
poroparietal bone EG, the lesion extended intracranially
causing repeated bouts of epilepsy which resolved fol⁃
lowing surgical ablation.
Discussion
Etiopathogenesis
The etiopathogenesis of LCH is unknown and
probably related to viral infection, enzyme of metabolic
obstacle, immunodeficiency or trauma. Distinctive
features of LCH are: (1) sensitive response to low-dose
radiation,(2) response to steroids,(3) spontaneous
remision in some untreated patients, and (4) features of
inflammatory process. Viral or other infectious agents
have been considered as its etiology because of the
disease's responsiveness to antibiotics and steroids.
However, no pathgens have been isolated from LCH
lesions. Data supporting metabolic, genetic or
immunodeficiency factors are insufficient[7]. Willman et
al tested for clonal histiocytes in specimens of various
forms of LCH usng X-linked polymorphic DNA probes.
The results suggested that this disease might represent a
clonal neoplastic disorder with highly variable biological
behaviors［8］. Mosnier et al reported cases of Langerhans'
cell histiocytosis located adjacent to or within the area
of the endolymphatic sac region [9]. The fact that the
endolymphatic sac plays an immunologic role in the
inner ear suggests that the infiltration of the Langerhans'
cell may have originated from the sac. There is no
conclusive evidence showing that LCH is a malignant
neoplastic process. The non-neoplastic nature of the
disease is supported by its responsiveness to steroid
therapy or to low doses of radiation in many patients and
by spontaneous resolution of lesions in some untreated
patients. Immunologic aberrations have been discovered
in patients with LCH, leading to the current concept that
LCH represents a disorder of immune response. A
relatively accepted view is that LCH is a special
inflammatory reaction caused by an unknown factor［7, 8］.
Clinical manifestation
Figure 3. a. High-power photomicrograph of HSC specimen showing small lipid vesicles in the cytoplasm of histiocytes
（Langerhans' cell）, known as "foam cells"（arrows）, surrounded by infiltration of inflammatory cells（HE, ×400）. b. Electron
microscopic photomicrograph showing typical histiocyte（Langerhans' cell）proliferation with abundant cytoplasm, lobulated,
irregular or kidney-shaped nucleus, clearly visible nucleolus and nuclear menbrance invagination（× 2800）. c. Electron
microscopic photomicrograph showing characteristic rod- and racket-shaped Birbeck (Langerhans') granules（asterisks）in
the cytoplasm of a histiocyte（× 4200）.
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Clinical symptoms in LCH depend on the extent of
bone and extraskeletal involvement. The clinical
manifestation of LCH can result from histiocytic
infiltration of a variety of organs including bone, skin,
lymph nodes, thymus, liver, spleen, lung, bone marrow,
and central nervous system. Multifocal infiltration may
present with bilateral temporal bone involvement, which
is a very rare condition［10, 11］. Three clinical syndromes, i.
e., EG, HSC and LS, have been described［1, 2］.
EG generally involves bones alone. Skull is most
frequently involved. Temporal bone lesions are also
common. Swelling in the temporal area, localized pain,
otorrhea and hearing loss are the frequent symptoms.
EG can occur at any age, but approximately 50% of
patients are diagnosed before age of 5 years and 75%
before age of 20 years. The clinical course is typically
benign with an excellent prognosis.
LS is a disseminated LCH that characteristically
presents in infants and children below the age of 3
years. Multi-organ involvement is its regular pattern,
and clinical features include fever, rash,
lymphadenopathy, hepatosplenomegaly, dyspnea, and
blood dyscrasias. Its disease course is progressive with
rapid deterioration and a high mortality rate.
HSC is also a systemic LCH with the clinical
severity intermediates between that of localized EG and
disseminated LS. Chiefly, multifocal osseous lesions
complicated by limited extraskeletal involvement of
skin, lymph nodes, and viscera characterize the
syndrome. The classic triad of DI secondary to posterior
pituitary and/or hypothalamic disease, exophthalmos
secondary to orbital bone involvement and osteolytic
skull lesions is found in about 10-15% of patients［11］.
Diagnosis
Diagnosis of LCH can be difficult as these lesions
mimic other common conditions seen by the
otolaryngologist, including otitis externa, acute
mastoiditis. Diagnosis should be based on the
combination of clinical, radiological and histopathologic
findings. The clinical manifestations of LCH are
aforementioned.
The radiological appearances of osseous LCH depend
on the involved sites and the disease stage. The
temporal bone, particular the petrous pyramid and
mastoid, is the most commonly involved site at the skull
base. Lesions also occur in the sella turcica and orbits.
The localized form of LCH commonly refers to EG,
a solitary defect of osteolysis is founded in the temporal
bone. The lesions typically appear lytic but may have
well-demarcated margins with or without reactive
sclerosis[7]. The chronic recurring disseminated form of
LCH is also known as HSC. The radiograph of skull
shows multiple osteolytic defects as moth-eaten and
mouse-bite shape, creating a map-like or geographic
margin known as "geographic skull"［5］.
CT clearly delineates osseous involvement, includ⁃
ing erosions of small structures of the bony labyrinth
and ossicular chain. CT also better differentiates the
margin of granulation mass from the brain tissue and ex⁃
tra-temporal tissue. This improved delineation of both
the osseous and soft tissue components of temporal bone
LCH. CT scan allowed more precise determination of
the extent of the disease than traditional radiographic
methods do. CT also has an important role in monitoring
disease activity and response to treatment[12]. More com⁃
mon solid lesions such as cholesteatoma and metastatic
malignancy can confuse CT findings[11].
MRI provides excellent identification of the lesion
extent. MRI effectively aids in defining the intracranial
extent of destructive temporal bone lesions[13], and
enhances diagnostic accuracy before biopsy. In addition,
patients may have coexisting central nervous
system(CNS) involvement adjacent to, or remote from,
osseous lesions. MRI of the temporal bone in patients
with LCH is ideal for evaluating the extracranial and
intracranial extent of the soft-tissue mass, usually into
the middle cranial fossa, and of patency of adjacent
vascular structures. Furthermore, it is complementary to
computed tomography (CT) in the assessment of osseous
erosion ［14］. It is the imaging modality of choice to
evaluate patients with suspected CNS involvement of
LCH, which includes lesions of the infundibulum,
cerebrum, cerebellum, and extra-axial spaces. MRI
features of LCH in the hypothalamus and the cerebral
hemispheres were described by Graif［15］. Sagittal images
provide the best anatomic and topographic evaluation of
the lesion. Moore stated that the involved hypothalamic
nuclei, which showed high signal foci on T2-weighted
MRI, completely resolved after effective chemotherapy.
It suggests that MRI is valuable for monitoring the
response to therapy［16］.
Three clinical types of LCH are of unifying
histopathological features, proliferation and infiltration
of histiocytes, but each of the three types has its
distinguishing features. LS is a proliferation stage with
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main manifestations of reactive proliferation and
infiltration of histiocytes. The histiocytes are well
differentiated with ellipse or kidney-shaped nucleus,
clear euchromatin and a nucleus membrane. Infiltration
of a few eosinophils, polymorphonuclear giant cells,
plasmacytes and lymphocytes were detected. EG is a
granuloma stage, over the background of histiocyte
proliferation, infiltration of numerous eosinophils,
lymphocytes, plasmacytes and neutrophils is seen. HCS
is a xanthomatosis stage, xanthomatosis reaction is
distinguished by large amount of thecacells with
infiltration of eosinophils, lymphocytes and plasmacyt-
es ［3］. Immunohistochemical studies are also highly
sensitive and helpful in increasing the level of
diagnostic certainty. Langerhans' cell stains positive for
adenosin triphophatase, a-D-mannosidase, and S-100
protein［5, 7］.
Ultrastructural studies of lesional tissue reveal Lang⁃
erhans' cell with characteristic intracytoplasmic
rod-shaped and tennis racket-shaped granules called
Birbeck or Langerhans' granules, which are necessary
for definitive diagnosis in accordance with the Histio⁃
cyte Society criterion［５，７，17］.
Differential diagnosis
The three syndromes are the same disorder of
different clinical stages and types without strict limit
among each other. Transformation and overlapping may
occur among them. Differential diagnosis depends on
the site and extent of involvement, the stage of the
disease and the age of patient［3］.
Schuknecht attempted to categorize patients with
LCH of the temporal bone into two clinicopathologic
types[3]. Alessi deliberately avoided the term EG, HSC
and LS, because he believed these eponyms offer no
help in understanding the disease types and prognosis.
Alessi listed characteristic treatment and prognosis for
each type. This system is to provide a simple, accurate,
easy to remember and practical criterion[4].
Generally, systemic manifestations of the LCH are
so remarkable that ear findings are overlooked.
Furthermore, otologic findings resemble other more
common ear disorders and metastasic lesions of the
temporal bone. Variation of normal, surgical or
traumatic defect, chronic infections, other
granulomatous disorders and certain neoplasms may
confuse LCH in the temporal bone. Schuknecht depicted
a selected differential diagnosis including 14 diseases[3].
Treatment and Prognosis
Treatment consists of surgery(curettage, or total
excision), radiation therapy, chemotherapy, or some
combination of these techniques. Chemotherapy is
rarely used in patients with isolated bone lesions.
Therapy for unifocal temporal LCH includes surgical
resection, radiotherapy or both[3-7, 11, 16].
Lesions limited to the mastoid cortex may be treated
by cortical mastoidectomy. Large destructive lesions
involving both middle ear and mastoid, small lesions
arising within the petrotympanic portion, and recurrent
or residual temporal bone disease are indications for
radiotherapy. Many authors apply radiation therapy
alone or in combination with surgical curettage.
Otorrhea, postauricular swelling, and conductive
hearing loss recover or considerably improve after
radiotherapy; only sensorineural hearing loss due to otic
capsule disruption appears irreversible. A treatment
course of 600 to 1000 cGY is recommended. Such
dosages are not only effective but also low enough to
avoid complications. Cure rate for unifocal osseous LCH
are greater than 85-90% . Attamps to control DI with
irradiation to the hypothalamic region yielded poor
results［3, 11］. When the temporal bone is one of the
multiple sites involved in multifocal ossecus LCH
without visceral involvement, radiotherapy may be used
as a single therapy modality. An alternative use of
chemotherapy should be deliberately considered in
young children. Chemotherapy should be used in
aggressive and refractory cases. Chemotherapy scheme
includes cyclophosphamide(CTX); vincristini (VCR) and
prednisolone etc［15］. Irving et al presented the rapidly
effective and long-term benefit results of topical 20%
nitrogen mustard (mustin) ear drops in the management
of children who had LCH with otitis external［18］.
In our series, except the LS patient who died of
secondary lung infection, all 20 cases with EG and HSC
were treated with combined surgery, radiation and
pharmocological therapy. EG showed the best results.
Despite the extensive lesion involvement, all patients
with HSC survived. In total, 18 patients were cured
(85%) in our series, with 6 patients continuing to suffer
from comorbid refractory DI and dwarfism(28% ).
Prognosis in LCH depends on the patient's age and
extent of systemic involvement. Younger patients tend to
have more severe diseases. Children less than 1 year,
particular those with vital organ dysfunction, often do
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not respond to any treatment. Children older than 1 year
tolerate chemotherapy better than infant and tend to
respond better. Although a substantial number of
patients with disseminated LCH respond to therapy,
there is no definitive evidence that therapeutic
intervention prevents long-term sequela or shortens the
clinical course of LCH. Complete remission for chronic
and acute fulminant forms of LCH as well as sequelae
are difficult to achieve.
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